Literature DB >> 17237960

[Wilms' tumor - update 2007].

H Reinhard1, R Furtwängler, N Graf.   

Abstract

Due to the close interdisciplinary work of surgeons, radiologists and oncologists, the prognosis for Wilms' tumor (the most common renal tumor in childhood) has been dramatically improved over the last few decades. The treatment of such tumors is currently carried out worldwide by two study groups, in North America the National Wilms' Tumor Study (NWTS) and in Europe the Society of Paediatric Oncology (SIOP). Here we present an overview of the current treatment results and discuss future diagnostic and therapeutic strategies.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17237960     DOI： 10.1007/s00120-006-1283-4

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  8 in total

1.  Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood.

Authors:  Gordan M Vujanić; Bengt Sandstedt; Dieter Harms; Anna Kelsey; Ivo Leuschner; Jan de Kraker
Journal:  Med Pediatr Oncol       Date:  2002-02

2.  High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor.

Authors:  Jeffrey S Dome; Carol A Bockhold; Sierra M Li; Scott D Baker; Daniel M Green; Elizabeth J Perlman; D Ashley Hill; Norman E Breslow
Journal:  J Clin Oncol       Date:  2005-09-19       Impact factor: 44.544

3.  Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters.

Authors:  B Zirn; O Hartmann; B Samans; M Krause; S Wittmann; F Mertens; N Graf; M Eilers; M Gessler
Journal:  Int J Cancer       Date:  2006-04-15       Impact factor: 7.396

4.  Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.

Authors:  D M Green; N E Breslow; J B Beckwith; J Z Finklestein; P E Grundy; P R Thomas; T Kim; S J Shochat; G M Haase; M L Ritchey; P P Kelalis; G J D'Angio
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

5.  Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.

Authors:  Paul E Grundy; Norman E Breslow; Sierra Li; Elizabeth Perlman; J Bruce Beckwith; Michael L Ritchey; Robert C Shamberger; Gerald M Haase; Giulio J D'Angio; Milton Donaldson; Max J Coppes; Marcio Malogolowkin; Patricia Shearer; Patrick R M Thomas; Roger Macklis; Gail Tomlinson; Vicki Huff; Daniel M Green
Journal:  J Clin Oncol       Date:  2005-08-29       Impact factor: 44.544

Review 6.  Current therapy for Wilms' tumor.

Authors:  Monika L Metzger; Jeffrey S Dome
Journal:  Oncologist       Date:  2005 Nov-Dec

7.  Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.

Authors:  H Reinhard; O Semler; D Bürger; U Bode; M Flentje; U Göbel; P Gutjahr; I Leuschner; E Maass; F Niggli; H G Scheel-Walter; M Stöckle; J W Thüroff; J Tröger; A Weirich; D von Schweinitz; A Zoubek; N Graf
Journal:  Klin Padiatr       Date:  2004 May-Jun       Impact factor: 1.349

8.  Wilms' tumor in adults: results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) Study.

Authors:  Harald Reinhard; Schahin Aliani; Christian Ruebe; Michael Stöckle; Ivo Leuschner; Norbert Graf
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544
  8 in total
  1 in total

1.  Secondary neoplasms after Wilms' tumor in Germany.

Authors:  Nasenien Nourkami; Rhoikos Furtwängler; Muhannad Alkassar; Norbert Graf
Journal:  Strahlenther Onkol       Date:  2009-08       Impact factor: 3.621
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.